TY - JOUR
T1 - Evaluating the impact of multicancer early detection testing on health and economic outcomes
T2 - Toward a decision modeling strategy
AU - Lipscomb, Joseph
AU - Horton, Susan
AU - Kuo, Albert
AU - Tomasetti, Cristian
N1 - Funding Information:
Joseph Lipscomb reports travel support from the International Union Against Cancer, the American Cancer Society, and the Mayo Clinic during the conduct of the study and grants from the National Cancer Institute and the Centers for Disease Control and Prevention outside the submitted work. Susan Horton reports travel support from the International Union Against Cancer, the American Cancer Society, and the Mayo Clinic during the conduct of the study; grants from the Canadian Institutes for Health Research, the Institute for Catastrophic Loss Reduction, and the Brocher Foundation; and personal fees from PATH outside the submitted work. Albert Kuo reports salary support from the John Templeton Foundation during the conduct of the study and has a patent pending through Johns Hopkins University outside the submitted work. Cristian Tomasetti reports grants from the John Templeton Foundation during the conduct of the study and royalties under an agreement between Exact Sciences Corporation and Johns Hopkins University outside the submitted work.
Publisher Copyright:
© 2022 American Cancer Society
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Emerging data provide initial support for the concept that a single, minimally invasive liquid biopsy test, performed in conjunction with confirmatory radiologic or other diagnostic testing, when indicated, could be deployed on a broad scale to screen individuals for multiple types of cancer. Ideally, such a test could do this in a way that yields a clinically important percentage of true-positive indications of cancer while minimizing false-positive signals. Modern decision modeling approaches can and should be deployed to investigate the health and economic consequences of such multicancer early detection (MCED) testing within defined at-risk populations. In this paper, through small-scale analyses involving 3 hypothetical MCED-detectible cancers, the authors illustrate the potential for MCED testing to be cost-effective, along with the pivotal role of test-induced stage shift on results. The time is ripe for additional, prospective investigations of the clinical value of MCED testing, the benefits versus the risks for screened populations, and the overall projected impact on health outcomes and costs over time.
AB - Emerging data provide initial support for the concept that a single, minimally invasive liquid biopsy test, performed in conjunction with confirmatory radiologic or other diagnostic testing, when indicated, could be deployed on a broad scale to screen individuals for multiple types of cancer. Ideally, such a test could do this in a way that yields a clinically important percentage of true-positive indications of cancer while minimizing false-positive signals. Modern decision modeling approaches can and should be deployed to investigate the health and economic consequences of such multicancer early detection (MCED) testing within defined at-risk populations. In this paper, through small-scale analyses involving 3 hypothetical MCED-detectible cancers, the authors illustrate the potential for MCED testing to be cost-effective, along with the pivotal role of test-induced stage shift on results. The time is ripe for additional, prospective investigations of the clinical value of MCED testing, the benefits versus the risks for screened populations, and the overall projected impact on health outcomes and costs over time.
KW - cost-benefit analysis
KW - decision support techniques
KW - early detection of cancer/economics
KW - health care costs
KW - mass screening/economics
KW - quality-adjusted life-years
UR - http://www.scopus.com/inward/record.url?scp=85124282090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124282090&partnerID=8YFLogxK
U2 - 10.1002/cncr.33980
DO - 10.1002/cncr.33980
M3 - Article
C2 - 35133662
AN - SCOPUS:85124282090
SN - 0008-543X
VL - 128
SP - 892
EP - 908
JO - Cancer
JF - Cancer
IS - S4
ER -